Hemogenyx Pharmaceuticals PLC Equity Incentive Pool Increase and Option Grant (8828X)
28 April 2023 - 7:05PM
UK Regulatory
TIDMHEMO
RNS Number : 8828X
Hemogenyx Pharmaceuticals PLC
28 April 2023
28 April 2023
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Equity Incentive Plan Pool Increase and Grant of Share
Options
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that the
Company's Board of Directors has resolved to increase the pool for
the granting of share options, restricted shares, and restricted
share units under the Company's 2021 Equity Incentive Plan with
Non-Employee Sub-Plan by 60,000,000 shares, amounting to a total
pool of 90,000,000 shares.
The Company has also granted a total of 57,099,966 options over
ordinary shares in the capital of the Company ("Share Options") to
the Company's co-founder and CEO, Dr Vladislav Sandler. The Share
Options vest in two tranches of 22,839,986 Share Options ("Tranche
1") and 34,259,980 Share Options ("Tranche 2"). The Tranche 1 Share
Options are being granted in recognition of Dr Sandler's work in
bringing HEMO-CAR-T to the point of preparing it for submission of
an Investigational New Drug ("IND") application to the US Food and
Drug Administration ("FDA") for approval. The Tranche 2 Share
Options will vest upon authorization by the FDA for the Company to
commence clinical trials of HEMO-CAR-T.
The details of the Share Options granted are set out below:
Name Position Number of Exercise Vesting Date/Criteria Expiry Date
Share Options Price (pence)
Granted
Dr Vladislav CEO 22,839,986 Tranche 1: Tranche 1: Tranche 1:
Sandler 2.5p immediately 27 April
34,259,980 Tranche 2: 2028
2.875p Tranche 2: Tranche 2:
upon authorisation 5 years from
by the FDA vesting date
to commence
clinical trials
of HEMO-CAR-T
--------- --------------- --------------- ---------------------- --------------
Following the grant of the Share Options, there are, in
aggregate, 92,399,552 ordinary shares of 1 penny each in the
Company under option held by directors, employees and members of
the Scientific Advisory Board of the Company arising from awards
made under the Company's original Employee Plan, Non-Employee Plan
and the 2021 Equity Incentive Plan with Non-Employee Sub-Plan.
These represent 8.09% of the issued ordinary share capital of the
Company.
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Peter Redmond, Director peter.redmond@hemogenyx.com
Tel: +44 (0)20 3470
SP Angel Corporate Finance LLP 0470
Matthew Johnson, Vadim Alexandre,
Adam Cowl
Tel: +44 (0)20 7469
Peterhouse Capital Limited 0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
Notification and public disclosure of transactions by persons
discharging managerial responsibilities ("PDMR") and persons
closely associated with them ("PCA"):
1. Details of PDMR/person closely associated with them
a) Name Dr Vladislav Sandler
--------------------------- --------------------------------------
b) Position/status CEO, Executive Director
--------------------------- --------------------------------------
c) Initial notification/ Initial notification
amendment
--------------------------- --------------------------------------
2. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description of Options over ordinary shares of 1p
the financial of Hemogenyx Pharmaceuticals plc
instrument Identification code GB00BYX3WZ24
--------------------------- --------------------------------------
b) Nature of the Grant of options
transaction
--------------------------- --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) 1. 2.5p 1. 22,839,986
2. 2.875p 2. 34,259,980
--------------------
--------------------------- --------------------------------------
d) Aggregated information Price(s) Volume(s)
- Aggregated N/A - variable 57,099,966
volume -----------
- Price
--------------------------- --------------------------------------
e) Date of the transaction 28/04/2023
--------------------------- --------------------------------------
f) Place of the Outside of a trading venue
transaction
--------------------------- --------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEKZGZDRRLGFZG
(END) Dow Jones Newswires
April 28, 2023 05:05 ET (09:05 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024
